Application of orsythoside A in preparation of medicament for treating herpes simplex

A technology of forsythiaside and herpes simplex, which is applied in the field of medicine and can solve the problem of few studies on the anti-herpes virus pharmacological activity of forsythiaside

Inactive Publication Date: 2011-02-09
SHANGHAI YOUSEEN NEW MEDICINE EXPLOITION
View PDF6 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] At present, there are few studies on the anti-herpes virus pharmacological activity of forsythiaside in the prior art

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of orsythoside A in preparation of medicament for treating herpes simplex
  • Application of orsythoside A in preparation of medicament for treating herpes simplex
  • Application of orsythoside A in preparation of medicament for treating herpes simplex

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] Embodiment 1 (forsythiaside anti-herpes simplex type II virus test in vitro)

[0014] 1. Experimental purpose: To observe the inhibitory effect of forsythiaside on herpes simplex type II virus in vitro.

[0015] 2. Experimental materials:

[0016] 1. Test drug: Forsythiaside, provided by Shanghai Yusen New Drug Development Co., Ltd., batch number: 060909 (For the preparation method of this drug, please refer to Chinese patents CN101081855A, CN101081856A, CN101081857A, CN1899382A, CN101209286A.)

[0017] 2. Positive control drug: Acyclovir for injection, produced by Hubei Qianjiang Pharmaceutical Co., Ltd., batch number 20070302

[0018] 3. Virus strain: herpes simplex virus (HSV) standard strain type II 333 strains, provided by the Institute of Pharmaceutical Biotechnology, Chinese Academy of Medical Sciences, Beijing.

[0019] 4. Vero cells

[0020] 3. Experimental method

[0021] 1. Drug cytotoxicity test:

[0022] Vero cells were cultured in a 96-well culture pl...

Embodiment 2

[0035] Embodiment 2 (forsythiaside anti-herpes simplex type II virus test in vivo)

[0036] 1. Purpose of the test:

[0037] To observe the pharmacodynamic effect of forsythiaside on the inhibition of vaginitis induced by herpes simplex virus HSV-II in mice in vivo.

[0038] 2. Test materials:

[0039] Test drug: the same test drug as in Example 1.

[0040] Positive control drug: the same positive control drug as in Example 1.

[0041] Animal: Kunming mouse, weighing 17-20 grams, female. Provided by the Department of Laboratory Animal Science, Fudan University, license number: scxk Shanghai 2007-0002.

[0042] Strain: herpes simplex virus (HSV) standard strain type II 333, provided by the Institute of Pharmaceutical Biotechnology, Chinese Academy of Medical Sciences, Beijing.

[0043] Experimental drug solution preparation:

[0044] (1) The test drug for the test solution

[0045] A.24mg / cm 2 Dosage group: take forsythiaside freeze-dried powder and dissolve it in physi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the pharmaceutical field of traditional Chinese medicine, relating to application of a traditional Chinese medicine extract of orsythoside A in the preparation of a medicament for treating herpes simplex. In the invention, the effect of the orsythoside A against herpes simplex viruses is researched through in vitro and in vivo mouse tests. Experimental results show that the orsythoside A has obvious inhibiting effect on the herpes simplex II-type viruses of the mouse in vitro and in vivo, and the effect and dosage are in a response relationship.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a new medicine application of forsythiaside. Background technique [0002] The diameter of herpes simplex virus is about 120-150 microns. It is composed of three concentric structures of envelope, body coat and capsid. can be destroyed. Humans are the only natural host of herpes simplex virus, and 80-90% of the population is infected, and 10% are asymptomatic. [0003] Herpes simplex virus can be divided into two types: type I and type II. Type I herpes disease is mainly transmitted through close contact with the respiratory tract, skin and mucous membranes, and infects the skin, mucous membranes and organs above the waist. Such as causing inflammation and herpes of the mucous membranes of the lips, nasal vestibule, conjunctiva, throat, and herpes around the mouth and mouth, 99% are caused by type I herpes virus infection. Type II herpes virus mainly exists in wom...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61P31/22A61K31/7032
Inventor 玄振玉
Owner SHANGHAI YOUSEEN NEW MEDICINE EXPLOITION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap